QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,147 signal articles · 105 in last 24h · 178,672 total before filter · latest 1h ago

105last 24h

3127last 7d

510● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: MRKSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Zacks3d agobullish

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Trefis3d agoneutral

Is Regeneron Stock Riskier Than It Looks?

ABBV AMGN BMY MRK PFE SPGI ^GSPC

Trefis3d agoneutral

Why Did Pfizer Stop Talking Up This Business?

ABBV BMY JNJ LLY MRK PFE

24/7 Wall St.4d agoneutral

SCHD Gets the Attention, but This Shareholder Yield ETF Measures Something Bigger

Trefis4d agoneutral

What Could Go Wrong At Gilead From Here?

ABBV BMY GILD JNJ MRK PFE SPGI ^GSPC

Trefis4d agoneutral

Is Regeneron Stock Increasing Your Market Risk?

ABBV AMGN BMY MRK PFE SPGI ^GSPC

CNW Group4d agobullish

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

AMGN GILD MRK VRTX ^DJI ^GSPC ^IXIC

Trefis4d agoneutral

Was There Any Sign Regeneron Stock Would Run?

ABBV AMGN BMY MRK PFE

Simply Wall St.4d agoneutral

Bio-Techne (TECH), What Is Behind The Fresh Attention Now?

MT Newswires4d agoneutral

Medicenna Therapeutics Says Enrollment for Phase 1/2 Study for It MDNA11 Drug Complete

GlobeNewswire4d agoneutral

Downstream Processing - Global Strategic Business Report 2026: Capitalize on 15.7% CAGR to US$128.9 Billion by 2032 as Danaher, Merck, Sartorius, and Thermo Fisher Reshape Biomanufacturing

MT Newswires4d agoneutral

Daiwa Securities Adjusts Merck & Co Price Target to $160 From $143

GlobeNewswire4d agoneutral

Glycomics / Glycobiology - Global Strategic Business Report 2026: Capitalize on a $4.5 Billion Market by 2032 | Agilent, Bruker, Danaher, Merck, and Thermo Fisher Battle for Share

Trefis4d agoneutral

Is Eli Lilly Stock Increasing Your Market Risk?

ABBV AMGN JNJ LLY MRK PFE SPGI ^GSPC

Investor's Business Daily4d agobullish

Stock Market Today: Dow Surges Nearly 1,000 Points On Election; Musk-Led SpaceX, Tesla Dive (Live Coverage)

AAPL AMD AMGN CVX MRK QQQ SPCX TSLA+2

Trefis4d agobullish

The One Thing To Settle Before Buying Eli Lilly Stock

ABBV AMGN JNJ LLY MRK PFE

Trefis4d agoneutral

If Johnson & Johnson Stock Looks Expensive, You Need To Read This

ABBV JNJ LLY MRK PFE

Barchart4d agoneutral

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Motley Fool5d agoneutral

Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success

MRK MRNA NVDA ^GSPC

Motley Fool5d agoneutral

3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively

MRK NVDA SMCI XOM

24/7 Wall St.5d agobullish

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial

LLY MRK MRNA PFE

TIKR5d agoneutral

Pfizer Is Pitched for Its Dividend. The November 3 Report Has to Show Cash Flow Covers It

ABBV MRK PFE UNH

24/7 Wall St.5d agoneutral

Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Simply Wall St.5d agobullish

Is Cancer And HIV Trial Wins Altering The Investment Case For Merck (MRK)?

Barrons.com5d agoneutral

The U.S. Stocks Quietly Winning the Chinese Drug Boom

GlobeNewswire5d agoneutral

Cell Dissociation - Global Strategic Business Report 2026: Capitalize on 13% CAGR as Market Hits $587.4M by 2032; Outmaneuver Thermo Fisher, Merck, Miltenyi Biotec and GE Healthcare

GlobeNewswire5d agoneutral

Competent Cells - Global Strategic Business Report 2026: Secure Share of the $3.2 Billion Market by 2032 - Agilent, Bio-Rad, GenScript, and Merck Drive 9.2% CAGR

GlobeNewswire5d agoneutral

Electrophoresis Equipment and Supplies - Global Strategic Business Report 2026: Secure Share of a $3.1 Billion Market by 2032, Led by Agilent, Bio-Rad, SCIEX, and Merck

MT Newswires5d agoneutral

Merck Begins Phase 3 Trial of Ohtuvayre in Chronic Obstructive Pulmonary Disease Exacerbations

Trefis5d agoneutral

What Could Derail Bristol Myers Squibb Stock?

ABBV BMY JNJ LLY MRK PFE SPGI